Showing results (1-10 of 88) with videos related to
Sort By:
Pageof 9
Journal of Pharmacy & Bioallied Sciences|July 11, 2025
A Comprehensive Overview of US-FDA-Approved Anticancer Drugs and Biologics in 2023: An Observational StudyAjay Kumar Shukla, Saurav MisraJournal of Basic and Clinical Physiology and Pharmacology|December 6, 2023
Evidences and therapeutic advantages of donanemab in the treatment of early Alzheimer's diseaseAjay Kumar Shukla, Saurav MisraJournal of Basic and Clinical Physiology and Pharmacology|April 15, 2022
An overview of post COVID sequelaeAjay Kumar Shukla, Saurav MisraEuropean Journal of Clinical Pharmacology|April 2, 2023
Teplizumab: type 1 diabetes mellitus preventable?Saurav Misra, Ajay Kumar ShuklaJournal of Basic and Clinical Physiology and Pharmacology|January 7, 2022
Antibody-dependent enhancement of virus infection and disease: implications in COVID-19Ajay Kumar Shukla, Saurav MisraJournal of Basic and Clinical Physiology and Pharmacology|October 24, 2022
Clinical implications of anti-idiotype antibodies in COVID-19Ajay Kumar Shukla, Saurav MisraJournal of Basic and Clinical Physiology and Pharmacology|January 6, 2023
Bispecific antibodies and its applications: a novel approach for targeting SARS-Cov-2Ajay Kumar Shukla, Saurav MisraJournal of Basic and Clinical Physiology and Pharmacology|August 7, 2025
Seladelpar: a comprehensive review of its clinical efficacy and safety in the treatment of primary biliary cholangitisAjay Kumar Shukla, Saurav MisraJournal of Basic and Clinical Physiology and Pharmacology|May 3, 2022
Antimicrobials in COVID-19: strategies for treating a COVID-19 pandemicAjay Kumar Shukla, Saurav MisraJournal of Basic and Clinical Physiology and Pharmacology|December 12, 2025
Efficacy and safety of Mirikizumab in the treatment of moderate to severe active ulcerative colitis: a systematic reviewAjay Kumar Shukla, Saurav Misra, Ravi Kant Narayan, et al.Pageof 9